Side-by-side comparison of AI visibility scores, market position, and capabilities
Epigenetic protein engineering company developing liquid biopsy detection tools for the $50B blood test market; backed by Harvard's George Church competing in cancer early detection diagnostics.
Epinoma is a San Francisco-based biotech company engineering proteins that read and write epigenetic signals — developing protein tools for earlier cancer and disease detection through liquid biopsy (blood tests that detect disease-specific epigenetic marks) and therapeutic interventions that modify epigenetic states to treat disease without permanently altering DNA sequence. A Y Combinator S21 graduate backed by George Church (Harvard genetics pioneer), seedToB, and SeaX Ventures with $125,000 raised, Epinoma achieved $1 million in revenue in 2024 with an 8-person team, targeting the $50 billion blood test development market.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.